Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery.
OBJECTIVE
To review the use of systemic hemostatic medications for reducing bleeding and transfusion requirements with cardiac surgery.


METHODS
Articles were obtained through computerized searches involving MEDLINE (from 1966 to September 2000). Additionally, several textbooks containing information on the diagnosis and management of bleeding associated with cardiac surgery were reviewed. The bibliographies of retrieved publications and textbooks were reviewed for additional references.


METHODS
Due to the large number of randomized investigations involving systemic hemostatic medications for reducing bleeding associated with cardiac surgery, the article selection process focused on recent randomized controlled trials, metaanalyses and pharmacoeconomic evaluations.


METHODS
The primary outcomes extracted from the literature were blood loss and associated transfusion requirements, although other outcome measures such as mortality were extracted when available.


RESULTS
Although the majority of investigations for reducing cardiac bleeding and transfusion requirements have involved aprotinin, evidence from recent meta-analyses and randomized trials indicates that the synthetic antifibrinolytic agents, aminocaproic acid and tranexamic acid, have similar clinical efficacy. Additionally, aminocaproic acid (and to a lesser extent tranexamic acid) is much less costly. More comparative information of hemostatic agents is needed retative to other outcomes (eg., reoperation rates, myocardial infarction, stroke). There is insufficient evidence to recommend the use of desmopressin for reducing bleeding and transfusion requirements in cardiac surgery, although certain subsets of patients may benefit from its use.


CONCLUSIONS
Of the medications that have been used to reduce bleeding and transfusion requirements with cardiac surgery, the antifibrinolytic agents have the best evidence supporting their use. Aminocaproic acid is the least costly therapy based on medication costs and transfusion requirements.
Erstad
B L
BL
Department of Pharmacy Practice & Science, College of Pharmacy, Tucson, AZ 85721-0207, USA. erstad@pharmacy.arizona.edu
D000614:Aminocaproates / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007611:Aprotinin / Q000191:economics / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D003422:Critical Care; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000627:therapeutic use*; D006331:Heart Diseases / Q000601:surgery; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D006490:Hemostatics; D007611:Aprotinin; D003894:Deamino Arginine Vasopressin